Category Archives: Dr. Lucey Vaccine Posts

First multivalent vaccine with a variant (B.1.351) begins: Will it protect against other E484K variants?

By on .

By Daniel R. Lucey MD, MPH, FIDSA On March 10 Moderna announced that it had begun vaccinating volunteers in a study of 60 persons previously “vaccinated with mRNA-1273 to receive a single booster dose of either: 20 µg of a variant-specific booster candidate, mRNA-1273.351, based on the B.1.351 variant first identified in the Republic of South Africa (N=20) […]

Brazil’s Minister of Health works to purchase more COVID Vaccine doses

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Thursday (March 4) a release on the PAHO COIVD-19 website stated: “The Brazil Ministry of Health announced the purchase of new COVID-19 vaccines; 138 million doses are expected to be incorporated in the National Immunization Program starting May 2021.” The day before (on March 3) the Brazil Ministry of Health […]

Will survivors of variant P.1 have antibodies that also neutralize B.1.351 — and vice versa?

By on .

By Daniel R. Lucey MD, MPH, FIDSA The SARS-CoV-2 variants first described in Manaus, Brazil “P.1.” and in South Africa “B.1.351” share at least five mutations including the antibody-evading changes at amino acids 484 and 417 in the spike protein. Potential cross-protection against the P.1 variant by the new Moderna-NIH B1.351 variant vaccine has been […]

The new Moderna/NIH B.1.351-specific vaccine study should add the P.1 variant

By on .

By Daniel R. Lucey MD, MPH, FIDSA Two manuscripts from Brazil, newly posted by accomplished researchers on preprint servers, report that the P.1 variant “associated with rapid transmission in Manaus” (by Faria N.  et al.) and reported in the U.S. and 28 other nations, “may escape from neutralizing antibodies generated in response to polyclonal stimulation […]

In March NIH will start the first variant-specific COVID vaccine study: Will this B.1.351-variant vaccine also induce some immunity to the P.1 variant?

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Friday (Feb. 26) National Institute of Allergy and Intections Diseases Director /NIH Dr. Anthony Fauci, announced plans to start vaccine studies for the first time using the variant B.1.351, now dominant in South Africa and present in the United States. It contains the E484K mutation and also […]

Moderna to test a “multivalent” COVID vaccine as well as single-valent boosters

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines […]

COVID vaccines in HIV-Positive recipients: Need for more data from the Novavax South Africa study and with other vaccine platforms

By on .

By Daniel R. Lucey MD, MPH, FIDSA The Jan. 28 Novavax press release that included preliminary results from its COVID-19 vaccine Phase 2b trial in South Africa appears to contain a significant difference in efficacy between volunteers who were HIV-positive and HIV-negative. If verified, then the implications warrant sustained attention for this protein-based adjuvanted COVID-19 […]

P.1 variant in Manaus, Brazil linked with COVID resurgence now despite reportedly crossing “theoretical herd immunity threshold” in October

By on .

When will new vaccines include the P.1. variant? By Daniel R. Lucey MD, MPH, FIDSA The resurging epidemic in the northern Brazil city of Manaus, Amazonas state, is another of the many cautionary lessons in humility this pandemic has shown the world over the past 13+ months.  On Jan. 26 the Pan American Health Organization […]

South Africa COVID vaccine results cause Novavax to begin work immediately on ”a booster and/or combination bivalent vaccine”

By on .

By Daniel R. Lucey MD, MPH, FIDSA Today the U.S.-based Novavax announced the results in a press release that its COVID-19 vaccine had 49.4% vaccine efficacy (95% Confidence Interval: 6.1 – 72.8) in its overall trial population in a Phase 2b trial in South Africa. Novavax stated that “approximately 90% of COVID-19 cases attributed to […]

Bivalent COVID vaccines: When will studies begin in order to stay ahead of the multiple known (and unknown) variants?

By on .

By Daniel R. Lucey MD, MPH, FIDSA The New York Times reported Monday (Jan. 25) that: “As a precaution, Moderna has begun developing a new form of its vaccine that could be used as a booster shot against the variant in South Africa . . . Moderna said it also planned to begin testing whether […]